吉西他滨联合顺铂治疗耐蒽环类及紫杉类晚期乳腺癌的效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Gemcitabine combined with Cisplatin in the treatment of anthracyclineresistant and taxane-resistant advanced breast cancer.Methods A total of 76 patients with advanced anthracycline-resistant and taxane-resistant breast cancer who were admitted to our hospital from March 2017 to June 2019 were selected as the subjects.They were divided into two groups according to the random number table method, with 38 cases in each group.In the control group, Vinorelbine combined with Cisplatin was used, and in the experimental group,Gemcitabine combined with Cisplatin was adopted.The treatment effect, quality of life, and adverse reactions were compared between the two groups.Results The disease control rate (DCR) and objective response rate (ORR) of the experimental group were 50.00% and 86.84%, which were higher than those of the control group accounting for 26.32%and 44.74%, respectively, and the differences were statistically significant (P＜0.05).The Karnofsky performance status(KPS) score was (85.56±12.86) points, which was higher than that of the control group ([75.78±12.48]points), and the difference was statistically significant (P＜0.05).There were no significant differences in the incidence of anemia, fever,hair loss, renal impairment or liver impairment (P＞0.05).Conclusion Gemcitabine combined with cisplatin is safe for patients with anthracycline-resistant and taxane-resistant advanced breast cancer.

Key words： Advanced breast cancer Gemcitabine Cisplatin Vinorelbine Quality of life

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Jun-cong

Cite this article:

HUANG Jun-cong. Effect of Gemcitabine combined with Cisplatin in the treatment of anthracycline-resistant and taxane-resistant advanced breast cancer[J]. 中国当代医药, 2020, 27(13): 58-60转70.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I13/58

[1]	杨思福，黄建瑾.吉西他滨联合长春瑞滨治疗耐药性晚期乳腺癌疗效观察[J].实用肿瘤杂志，2015，30（5）：462-464.
[2]	穆晓攀，杜晓明，张泽群，等.吉西他滨联合顺铂与紫杉醇联合顺铂方案治疗晚期肺鳞癌的临床疗效及不良反应观察[J].癌症进展，2016，14（4）：384-386.
[3]	律慧敏，张梦玮，牛李敏，等.晚期乳腺癌含洛铂联合化疗方案疗效及安全性[J].中华肿瘤防治杂志，2018，25（11）：803-806.
[4]	王俊斌，杨燕，汪子书，等.长春瑞滨或吉西他滨联合顺铂治疗转移性三阴性乳腺癌的临床疗效与安全性评价[J].中国临床药理学杂志，2016，32（1）：24-26.
[5]	周际昌.实用肿瘤内科学[M].北京：人民卫生出版社，2003：517.
[7]	刘伟，李健斌，王涛，等.蒽环类联合紫杉类方案在乳腺癌新辅助化疗中的有效性及安全性评价[J].临床肿瘤学杂志，2016，21（3）：228-232.
[8]	袁鹏，岳天华，肖艳华，等.紫杉醇及蒽环类药物联合化疗治疗晚期乳腺癌的临床疗效[J].实用癌症杂志，2015，30（3）：448-450.
[6]	Kaesmann L，Janssen S，Rades D.Karnofsky performance score，radiation dose and nodal status predict survival of elderly patients irradiated for limited-disease small-cell lung cancer[J].Anticancer Res，2016，36（8）：4177-4180.
[9]	宋志刚，庞东生，李星缘.卡培他滨联合吉西他滨治疗蒽环类耐药的转移性乳腺癌的效果比较[J].宁夏医科大学学报，2015，37（4）：459-461.
[10]	He K，Wang X，Guan X，et al.Vinorelbine plus gemcitabine or cisplatin as first-line treatment of HER2-negative advanced breast cancer[J].Anticancer Res，2017，37（10）：5647-5653.
[11]	张华一，郭钢.长春瑞滨联合卡培他滨治疗蒽环类或紫杉类药物治疗后复发转移乳腺癌[J].肿瘤研究与临床，2015，27（3）：199-201.
[12]	李莉，王友群，孙蔚莉，等.含铂方案治疗晚期乳腺癌临床研究[J].中华肿瘤防治杂志，2016，23（10）：657-662.
[13]	张杰，徐可，王少龙，等.吉西他滨联合长春瑞滨与联合紫杉醇姑息治疗铂类耐药的Ⅳ期鼻咽癌患者的随机对照试验[J].现代肿瘤医学，2016，24（5）：716-720.
[14]	田新庆，王文珍，王小娜.吉西他滨联合顺铂治疗三阴性晚期乳腺癌的疗效观察[J].肿瘤研究与临床，2015，27（1）：57-59.
[15]	王妍，刘海岭，张春侠，等.吉西他滨与长春瑞滨联合顺铂治疗晚期乳腺癌的临床效果分析[J].现代生物医学进展，2015，15（4）：676-678.